Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Ionis Pharmaceuticals stock (IONS)

Buy Ionis Pharmaceuticals stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals shares (IONS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.16 – an increase of 3.19% over the previous week. Ionis Pharmaceuticals employs 927 staff and has a trailing 12-month revenue of around $813.5 million.

Our top picks for where to buy Ionis Pharmaceuticals stock

Best for mobile experience

Go to site
  • Earn 4.5% interest on uninvested cash with Gold
  • Get up to $50,000 in instant deposits with Gold
  • Easy, user-friendly trading
  • Unlimited bonus amounts Oct 16-27

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Ionis Pharmaceuticals stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – IONS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Ionis Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Robinhood
Finder Score: 4.4 / 5: ★★★★★
Bonus
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Earn 1–3% on transfers from Oct 16–27
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
eToro
Finder Score: 4 / 5: ★★★★★
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.9%
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
No commission stock, ETF and options trades, with 4.9% interest on your options account balance and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ionis Pharmaceuticals stock price (NASDAQ: IONS)

Use our graph to track the performance of IONS stocks over time.

Ionis Pharmaceuticals shares at a glance

Information last updated 2024-10-15.
Latest market close$39.16
52-week range$35.95 - $54.44
50-day moving average $43.87
200-day moving average $44.77
Wall St. target price$61.72
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-2.52

Is it a good time to buy Ionis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ionis Pharmaceuticals price performance over time

Historical closes compared with the close of $37.84 from 2024-10-15

1 week (2024-10-11) -1.56%
1 month (2024-09-18) -10.67%
3 months (2024-07-18) -20.05%
6 months (2024-04-18) -7.28%
1 year (2023-10-18) -17.70%
2 years (2022-10-17) -18.66%
3 years (2021-10-18) 25.09%
5 years (2019-10-18) 55.79

Is Ionis Pharmaceuticals stock undervalued or overvalued?

Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ionis Pharmaceuticals's PEG ratio

Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Ionis Pharmaceuticals financials

Revenue TTM $813.5 million
Gross profit TTM $-257,866,000
Return on assets TTM -7.58%
Return on equity TTM -105.71%
Profit margin -44.96%
Book value $1.81
Market Capitalization $6.1 billion

TTM: trailing 12 months

Ionis Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Ionis Pharmaceuticals's total ESG risk score

Total ESG risk: 36.64

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Ionis Pharmaceuticals's environmental score

Environmental score: 5.18/100

Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Ionis Pharmaceuticals's social score

Social score: 26.17/100

Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Ionis Pharmaceuticals's governance score

Governance score: 13.29/100

Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Environmental, social, and governance (ESG) summary

Ionis Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 36.64
Total ESG percentile 62.18
Environmental score 5.18
Environmental score percentile 9
Social score 26.17
Social score percentile 9
Governance score 13.29
Governance score percentile 9

Ionis Pharmaceuticals share dividends

We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months.

Ionis Pharmaceuticals share price volatility

Over the last 12 months, Ionis Pharmaceuticals's shares have ranged in value from as little as $35.95 up to $54.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 0.384. This would suggest that Ionis Pharmaceuticals's shares are less volatile than average (for this exchange).

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Frequently asked questions

What percentage of Ionis Pharmaceuticals is owned by insiders or institutions?
Currently 0.781% of Ionis Pharmaceuticals shares are held by insiders and 95.658% by institutions.
How many people work for Ionis Pharmaceuticals?
Latest data suggests 927 work at Ionis Pharmaceuticals.
When does the fiscal year end for Ionis Pharmaceuticals?
Ionis Pharmaceuticals's fiscal year ends in December.
Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals's address is: 2855 Gazelle Court, Carlsbad, CA, United States, 92010
What is Ionis Pharmaceuticals's ISIN number?
Ionis Pharmaceuticals's international securities identification number is: US4622221004
What is Ionis Pharmaceuticals's CUSIP number?
Ionis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 462222100

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site